A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.

An open-label phase I/II study of single-agent obatoclax determined a maximum tolerated dose (MTD) and schedule, safety, and efficacy in older patients (≥ 70 yr) with untreated acute myeloid leukemia (AML).Phase I evaluated the safety of obatoclax infused for 3 hours on 3 consecutive days (3 h × 3 d...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Aaron D Schimmer, Azra Raza, Thomas H Carter, David Claxton, Harry Erba, Daniel J DeAngelo, Martin S Tallman, Carolyn Goard, Gautam Borthakur
Format:	Artigo
Jezik:	Inglês
Izdano:	Public Library of Science (PLoS) 2014-01-01
Serija:	PLoS ONE
Online dostop:	http://europepmc.org/articles/PMC4186779?pdf=render
Oznake:	Označite Brez oznak, prvi označite!